je.st
news
Tag: therapy
Carl Zeiss Meditec to invest in Oraya Therapy for treatment of wet AMD
2015-01-08 10:36:59| Industrial Machines - Topix.net
Carl Zeiss Meditec AG and Oraya Therapeutics, Inc. jointly announced today that the companies have entered into a collaboration agreement under which Carl Zeiss Meditec will provide funding to Oraya over a period of up to two years for the implementation of Oraya's growth strategy, and in turn receive rights in the company reaching up to a majority stake after two years. Oraya Therapeutics, Inc. has developed and commercialized a low energy X-ray radiation therapy for the treatment of wet age-related macular degeneration .
Tags: treatment
therapy
wet
carl
Teva to return rights to experimental cancer therapy
2014-12-30 17:21:14| Biotech - Topix.net
Teva Pharmaceutical Industries Ltd. is returning to OncoGenex the rights to a cancer drug, on which the companies had previously collaborated. Under the terms of an initial agreement, Teva will make a $27 million to OncoGenex of Bothell, Wash.
Tags: rights
return
cancer
experimental
Oxygen Therapy Products suit people of all ages.
2014-12-29 14:32:22| Industrial Newsroom - All News for Today
Available for adults, toddlers, and infants, Suction and Oxygen Therapy Products come with variety of hospital connections that conform to NFPA 99, ISO, and world standards, including FDA, HCA, and CE. Suction Regulators, offered in analog and digital versions, are suitable for continuous, intermittent, regulating suction, and full suction applications. Medical Air Flow Meters come in flow ratings of 200 cm³ for infants, 1 and 3.5 lpm for babies and toddlers, and 8 and 15 lpm for adults.
Tags: people
products
ages
therapy
Cell therapy site to create 150 jobs
2014-12-16 14:56:16| BBC News | Business | UK Edition
A new 55m cell therapy manufacturing centre in Stevenage is set to create up to 150 jobs, it is announced.
Data Investigating KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium
2014-12-10 14:30:00| Merck.com - Corporate News
Dateline City: SAN ANTONIO 18.5 Percent Overall Response Rate Observed in KEYTRUDA-Treated Patients with This Aggressive Form of Breast Cancer Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-086) SAN ANTONIO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall response rate of 18.5 percent with KEYTRUDA, the companys anti-PD-1 therapy, as assessed by RECIST v1.1, central review (n=5/27), in PD-L1 positive, advanced triple-negative breast cancer one of the most aggressive forms of breast cancer. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Claire Mulhearn, (908) 236-1118orInvestor:Joseph Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
san
presented
Sites : [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] next »